TriLink BioTechnologies, a Maravai LifeSciences company, has signed a non-exclusive License and Supply Agreement with Aldevron, a global Contract Development and Manufacturing Organization (CDMO). This agreement grants Aldevron customers access to TriLink’s CleanCap® mRNA capping technology for non-commercial use.
Under the terms of the agreement, TriLink will supply its patented CleanCap® M6, CleanCap® AG 3’OMe, CleanCap® AG, and CleanCap® AU cap analogs. These will be used in Aldevron’s mRNA development and manufacturing services, spanning from pre-clinical through Phase III programs.
CleanCap® technology is known for producing optimal 5’Cap structures with over 95% efficiency, which improves mRNA yield and process time compared to traditional capping methods. This agreement strengthens TriLink's objective to provide broader access to its critical mRNA capping technologies for therapeutic and vaccine development.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.